Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum],Drug Design, Development and Therapy

当前位置： X-MOL 学术 › Drug Des. Dev. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2021-02-12 , DOI: 10.2147/dddt.s300704
Shih-Lung Cheng , Ming-Lin Ho , Yun-Fa Lai , Hao-Chien Wang , Jeng-Yuan Hsu , Shih-Feng Liu , Ming-Shyang Huang , Cheng-Hung Lee , Ching-Hsiung Lin , Liang-Wen Hang , Yu-Chih Liu , Kuang-Yao Yang , Jia-Horng Wang

布地奈德/福莫特罗抗炎缓解和维持或丙酸氟替卡松/沙美特罗加按需短效 β2 激动剂：在没有最佳控制哮喘 (REACT) 研究的患者中的实际疗效 [勘误]

布地奈德/福莫特罗抗炎缓解和维持或丙酸氟替卡松/沙美特罗加按需短效 β2 激动剂：在没有最佳控制哮喘 (REACT) 研究的患者中的实际疗效 [勘误]

更新日期：2021-04-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文